biotech binary events Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : biotech binary events

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (35)	6/3/2003 12:05:38 PM
From: nigel bates	Read Replies (2) of 295

How significant is it that the expected completion date for the trial keeps going back a bit ? Quebec City, December 18, 2001 – Æterna Laboratories Inc. (TSE: AEL; NASDAQ: AELA) has completed patient recruitment for its international Phase III clinical trial in renal cell carcinoma. Some 280 patients are taking part in this trial at 50 investigative centres in 10 different countries in America and Europe. Conducted by an international team of oncology experts, the study aims to determine whether Neovastat can increase survival time in patients who have failed to respond to standard immunotherapy treatments. Trial results are expected in early 2003.... Montréal, Québec, June 12, 2002 – At the annual general meeting of Æterna Laboratories Inc., (TSX: AEL, Nasdaq: AELA), Dr. Éric Dupont, Chairman of the Board and CEO, told the shareholders that "Our Phase III clinical study of Neovastat in kidney cancer will be completed in less than 12 months and conclusive results could enable our Company to be the first to market an angiogenesis inhibitor in oncology"...

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next